Last reviewed · How we verify
BPaQM
BPaQM is a novel antimalarial compound that acts as a blood schizonticide to prevent malaria parasite multiplication in red blood cells.
BPaQM is a novel antimalarial compound that acts as a blood schizonticide to prevent malaria parasite multiplication in red blood cells. Used for Malaria (uncomplicated and severe).
At a glance
| Generic name | BPaQM |
|---|---|
| Also known as | Bedaquiline, Pretomanid, Quabodepistat, Moxifloxacin |
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | Antimalarial |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
BPaQM is being developed as a fast-acting antimalarial agent targeting the erythrocytic stage of Plasmodium parasites. It is designed to rapidly clear parasitemia and reduce malaria transmission, potentially offering advantages in treatment efficacy and safety profile compared to existing antimalarials.
Approved indications
- Malaria (uncomplicated and severe)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPaQM CI brief — competitive landscape report
- BPaQM updates RSS · CI watch RSS
- Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI